The BOADICEA model of genetic susceptibility to breast and ovarian cancer
暂无分享,去创建一个
D. Easton | D. Easton | P. Pharoah | A. Antoniou | P. Smith | D F Easton | Paula L. Smith | A C Antoniou | P P D Pharoah | P Smith | P. Smith
[1] E. Thomson,et al. Recommendations for Follow-up Care of Individuals With an Inherited Predisposition to Cancer: I. Hereditary Nonpolyposis Colon Cancer , 1997 .
[2] M. Stratton. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases , 1997, The Lancet.
[3] R. Goldbohm,et al. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58 209 women with breast cancer and 101 986 women without the disease , 2001, The Lancet.
[4] M. Gail,et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. , 1989, Journal of the National Cancer Institute.
[5] W. Thompson,et al. Family history of gynaecological cancers: relationships to the incidence of breast cancer prior to age 55. , 1991, International journal of epidemiology.
[6] K. Hemminki,et al. Risk factors and age‐incidence relationships for contralateral breast cancer , 2000, International journal of cancer.
[7] M O Leach,et al. The UK national study of magnetic resonance imaging as a method of screening for breast cancer (MARIBS). , 2002, Journal of experimental & clinical cancer research : CR.
[8] G. Giles,et al. Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study. , 1999, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[9] F. Couch,et al. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. , 1997, The New England journal of medicine.
[10] B. Rosen,et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. , 2001, American journal of human genetics.
[11] Douglas F Easton,et al. Cancer Incidence in BRCA1 mutation carriers. , 2002, Journal of the National Cancer Institute.
[12] M. J. van de Vijver,et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] S F Keevil,et al. Magnetic resonance imaging screening in women at genetic risk of breast cancer: imaging and analysis protocol for the UK multicentre study. UK MRI Breast Screening Study Advisory Group. , 2000, Magnetic resonance imaging.
[14] M. Stratton,et al. The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[15] G Parmigiani,et al. Evaluation of widely used models for predicting BRCA1 and BRCA2 mutations , 2004, Journal of Medical Genetics.
[16] K. Lange,et al. Programs for pedigree analysis: Mendel, Fisher, and dGene , 1988, Genetic epidemiology.
[17] E. Ostrander,et al. Frequency of BRCA1/BRCA2 mutations in a population‐based sample of young breast carcinoma cases , 2000, Cancer.
[18] N E Day,et al. Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population‐based study , 2001, Genetic epidemiology.
[19] J. Klijn,et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. , 2001, The New England journal of medicine.
[20] N. Rahman,et al. A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO , 2004, Journal of Medical Genetics.
[21] N. Risch. Linkage strategies for genetically complex traits. I. Multilocus models. , 1990, American journal of human genetics.
[22] M. Swift,et al. Cancer predisposition of ataxia-telangiectasia heterozygotes. , 1990, Cancer genetics and cytogenetics.
[23] N Risch,et al. Autosomal dominant inheritance of early‐onset breast cancer. Implications for risk prediction , 1994, Cancer.
[24] Nazneen Rahman,et al. Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations , 2002, Nature Genetics.
[25] D. Berry,et al. Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. , 1998, American journal of human genetics.
[26] J. Hopper,et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. , 2003, American journal of human genetics.
[27] R. Warren,et al. Magnetic resonance imaging screening in women at genetic risk of breast cancer: imaging and analysis protocol for the UK multicentre study , 2000 .
[28] Jessica G. Davis. Predictive Genetic Tests: Problems and Pitfalls , 1997, Annals of the New York Academy of Sciences.
[29] Giovanni Parmigiani,et al. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] T. Sellers,et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. , 2001, Journal of the National Cancer Institute.
[31] M. Skolnick,et al. A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene. Implications for presymptomatic testing and screening. , 1995, JAMA.
[32] K Offit,et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. , 1997, JAMA.
[33] N Risch,et al. Genetic analysis of breast cancer in the cancer and steroid hormone study. , 1991, American journal of human genetics.
[34] H. Olsson. Cancer risks in BRCA2 mutation carriers. , 1999, Journal of the National Cancer Institute.
[35] J Chang-Claude,et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. , 1998, American journal of human genetics.
[36] J. Peto,et al. High constant incidence in twins and other relatives of women with breast cancer , 2000, Nature Genetics.
[37] T. Walsh,et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. , 2001, JAMA.
[38] E. Thomson,et al. Recommendations for follow-up care of individuals with an inherited predisposition to Cancer. II. BRCA1 and BRCA2 , 1997 .
[39] M. Stratton,et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. , 1998, Journal of the National Cancer Institute.
[40] N E Day,et al. A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes , 2002, British Journal of Cancer.
[41] S. Seal,et al. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. , 1999, Journal of the National Cancer Institute.
[42] J. D. Thompson,et al. BRCA1 mutations in a population-based sample of young women with breast cancer. , 1996, The New England journal of medicine.
[43] D. Easton. How many more breast cancer predisposition genes are there? , 1999, Breast Cancer Research.
[44] S. Fisher,et al. Log odds of carrying an Ancestral Mutation in BRCA1 or BRCA2 for a Defined personal and family history in an Ashkenazi Jewish woman (LAMBDA) , 2003, Breast Cancer Research.
[45] A Howell,et al. Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme , 2003, Journal of medical genetics.
[46] The Polish Breast Cancer Consortium. Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations , 2002 .